Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

411
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
411
Hazard Ratio01:12

Hazard Ratio

200
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
200
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Cancer Therapy (excl. Chemotherapy And Radiation Therapy)
  11. Tace Vs. Tare For Hcc ≥ 8 Cm: A Propensity Score Analysis.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Cancer Therapy (excl. Chemotherapy And Radiation Therapy)
  11. Tace Vs. Tare For Hcc ≥ 8 Cm: A Propensity Score Analysis.

Related Experiment Video

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.2K

TACE vs. TARE for HCC ≥ 8 cm: A propensity score analysis.

Nhan Hien Phan1,2, Ho Jong Chun3, Jung Suk Oh1

  • 1Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Abdominal Radiology (New York)
|September 25, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) show similar effectiveness for large liver cancer. TARE is a safer option for unresectable hepatocellular carcinoma (HCC) larger than 8 cm.

Keywords:
Large hepatocellular carcinomaRadioembolizationTransarterial chemoembolization

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.1K
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.5K

Related Experiment Videos

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.2K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.1K
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.5K

Area of Science:

  • Hepatobiliary oncology
  • Interventional radiology
  • Oncologic imaging and response assessment

Background:

  • Hepatocellular carcinoma (HCC) larger than 8 cm presents a significant treatment challenge.
  • First-line treatment options for unresectable HCC include transarterial chemoembolization (TACE) and transarterial radioembolization (TARE).
  • Comparative data on the efficacy and safety of TACE versus TARE for large HCC is limited.

Purpose of the Study:

  • To compare the efficacy and safety of TARE and TACE as first-line treatments for unresectable HCC tumors greater than 8 cm.
  • To evaluate treatment response and survival outcomes between TACE and TARE groups.
  • To assess the incidence of adverse events associated with each treatment modality.

Main Methods:

  • Retrospective analysis of 129 patients with unresectable HCC > 8 cm treated between 2010-2021.
  • Propensity Score Matching (PSM) was used to create comparable groups of 40 patients each for TARE and TACE.
  • Tumor response assessed by mRECIST criteria; survival by Kaplan-Meier and Log-rank tests.

    • Main Results:

    • No significant difference in objective response rate (ORR) or disease control rate (DCR) at 3, 6, and 12 months between TACE and TARE.
    • Comparable overall survival (OS) and progression-free survival (PFS) post-PSM (OS: 33.2 months TACE vs. 38.1 months TARE; PFS: 11.5 months TACE vs. 9.1 months TARE).
    • TARE group had significantly lower rates of post-embolization syndrome (75% vs. 100%) and major adverse events (5% vs. 72%) compared to TACE post-PSM.

    Conclusions:

    • TARE and TACE demonstrate comparable efficacy for unresectable HCC > 8 cm.
    • TARE offers a superior safety profile compared to TACE in this patient cohort.
    • TARE should be considered a preferable first-line therapeutic option for patients with large unresectable HCC.